|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The glucocorticoid-insensitive hyperrresponsiveness in isolated human airways induced by IL-13 and IL-4 provides further evidence that the IL-4Rα pathway should be targeted as a new strategy for treatment of airway hyperresponsiveness in asthma.
|
31805312 |
2020 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings carry increasing relevance as IL-4Rα-targeted therapy is administered to human asthmatics.
|
31745261 |
2020 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate the effects of IL-4Rα blockade on the cellular level, we used flow cytometry to examine cytokine production after antigen stimulation in human T cells from patients with AD (n = 12) and healthy controls (n = 6).
|
31596502 |
2020 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candidates for systemic therapy (European Union).
|
31595499 |
2020 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that clinical improvement of AD that is mediated by interleukin-4 receptor α inhibition and the subsequent suppression of type 2 inflammation is correlated with increased microbial diversity and reduced abundance of S. aureus.
|
31252032 |
2020 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab targets IL-4Rα and is used for moderate-to-severe atopic dermatitis (AD).
|
31737955 |
2020 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trial data for dupilumab, a monoclonal antibody against the interleukin-4 receptor (IL-4Rα), have shown that it is safe and effective for the treatment of moderate to severe atopic dermatitis in patients whose disease is resistant to other therapies.
|
31286499 |
2020 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Inducible deletion of IL-4Rα demonstrated therapeutic effects, on established allergic airway disease and prevented the development of ovalbumin-induced airway hyperreactivity, eosinophilia and goblet cell metaplasia in allergen-sensitised mice.
|
31782803 |
2019 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Architectures of Childhood- and Adult-Onset Asthma Are Partly Distinct.
|
30929738 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We, therefore, devised a new strategy to increase the efficacy of the anti-IL-4Rα monoclonal antibody for the treatment of asthma and other atopic diseases by co-engaging CD32 and IL-4Rα on monocytic cells by choosing IgG classes or Fc mutations with higher affinities for CD32.
|
30950681 |
2019 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis.
|
31619474 |
2019 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma).
|
30488542 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Eczema
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD.
|
31509236 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma).
|
30488542 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody that binds to the α subunit of the IL-4 receptor (IL-4Rα) and has been approved for the treatment of adults with severe atopic dermatitis, has been shown in recent phase 3 trials to also have significant clinical benefits in the asthmatic population irrespective of baseline eosinophil counts.
|
30407206 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
In March 2017, dupilumab, a human anti-IL-4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate-to-severe AD.
|
30825336 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis and chronic sinusitis with nasal polyposis.
|
31838750 |
2019 |
|
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis.
|
31603635 |
2019 |
|
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics.
|
31707051 |
2019 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to target simultaneously the IL-4, IL-13, and IL-5 signaling pathways with a novel IL-4Rα/IL-5-bispecific antibody in a murine house dust mite (HDM) model of asthma.
|
29890236 |
2018 |
|
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To evaluate whether polymorphisms of IL4R (rs1805015), IL13 (rs20541), IL17A (rs2275913) and GSTP1 (rs1695) genes are associated with rhinitis and/or asthma in adults of Portuguese ancestry.
|
27561723 |
2018 |
|
Asthma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It has a potential role in identifying asthmatics who may be responsive to treatment with monoclonal antibody therapy directed against Type 2 cytokines, such as interleukin (IL)-13, IL-4 receptor subunit-α and immunoglobulin E. The clinical utility of periostin measurements depends on better understanding of factors that may affect serum periostin levels, such as race.
|
30574168 |
2018 |